Photocure Valuation
Is PHOO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PHOO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PHOO (NOK57.7) is trading below our estimate of fair value (NOK208.06)
Significantly Below Fair Value: PHOO is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHOO?
Key metric: As PHOO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is PHOO's PS Ratio? | |
|---|---|
| PS Ratio | 3.9x |
| Sales | NOK 462.30m |
| Market Cap | NOK 1.79b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.4x |
| Enterprise Value/EBITDA | -591.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PHOO's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.4x | ||
ANCR Animalcare Group | 2x | 3.8% | UK£148.5m |
APH Alliance Pharma | 1.3x | 5.2% | UK£245.1m |
REDX Redx Pharma | 13.9x | -37.6% | UK£58.3m |
AGY Allergy Therapeutics | 4.3x | 19.2% | UK£238.8m |
PHOO Photocure | 3.9x | 15.7% | NOK 1.8b |
Price-To-Sales vs Peers: PHOO is good value based on its Price-To-Sales Ratio (3.9x) compared to the peer average (6.4x).
Price to Sales Ratio vs Industry
How does PHOO's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
EAH ECO Animal Health Group | 0.5x | 5.9% | US$54.43m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: PHOO is expensive based on its Price-To-Sales Ratio (3.9x) compared to the European Pharmaceuticals industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is PHOO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHOO's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Formycon
€848.4m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.50
7D
4.3%
1Y
-21.3%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€63.05
7D
1.3%
1Y
13.6%
Regeneron Pharmaceuticals
US$79.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$745.13
7D
-2.1%
1Y
-6.5%